Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 12Glioblastoma 12Carcinoma, Non-Small-Cell Lung 12Prostatic Neoplasms 11Oropharyngeal Neoplasms 10Breast Neoplasms 10Glioma 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Esophageal Neoplasms 6Sarcoma 5Neoplasm Metastasis 5Mouth Neoplasms 5Carcinoma 5Burkitt Lymphoma 5Astrocytoma 5Uterine Cervical Neoplasms 4Rhabdomyosarcoma 4Pancreatic Neoplasms 4Liposarcoma 4Laryngeal Neoplasms 4Histiocytoma, Malignant Fibrous 4Gliosarcoma 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Sarcoma, Synovial 3

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Radiation × 90 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡